Sanofi Q1 profit slips on generic competition, forex effects
Labcorp will acquire all of the bankrupt firm's assets on a going concern basis for $239 million in cash consideration and other non-cash
Zydus launches Mirabegron Extended-Release Tablets in the US
The threat of low-cost competition in the US to Astellas’ Myrbetriq for urinary incontinence has moved a step closer after a court recommended denying an injunction on the launch of generics.
ROCKVILLE, MD – There is a need for the scientific community to explore the use of additional strength biowaivers for modified release (MR) drugs given the increasing market demand for these “patient centric” products, said Robert Lionberger, director of the US Food and Drug Administration’s (FDA) Office of Research and Standards in the Office of Generic Drugs.
An Indian industrialist wants to buy Biogaran, the French number one in generics
Generic drugs are often hailed as an effective cost-containment measure for healthcare systems that often have outdated or ineffective financing mechanisms. Despite their increasing usage, a significant proportion of healthcare professionals (HCPs) still tend to favor branded drugs, finds GlobalData’s, a leading data and analytics company.
Endo sues FDA over its handling of generic Adrenalin approvals
Generic drugs still passed over for brands, study finds: While more doctors are prescribing generic drugs, the majority of doctors still prefer brand name drugs, according to a new GlobalData survey. Almost 40% of physicians would prescribe branded drugs for patients if cost wasn’t a factor. Market research head Urte Jakimaviciute noted the continued importance of drug marketing and brand loyalty which “plays a crucial role in the pharmaceutical industry, as it impacts the generation of sales and revenue, as well as acts as an entry barrier to competitors once patent protection expires.”
Generic drugs feature the exact same active ingredient, strength and dosing regimen as their brand-name predecessors, but, if it weren’t for their typically lower prices, they still wouldn’t be many doctors’ first choice.